Thymic stromal lymphopoietin and interleukin-4 mediate the pathogenesis of halothane-induced liver injury in mice

Authors

  • William R. Proctor,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Mala Chakraborty,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Aaron M. Fullerton,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Midhun C. Korrapati,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Pauline M. Ryan,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Kenrick Semple,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Jeffrey C. Morrison,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Julia D. Berkson,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Lynette S. Chea,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Qian Yang,

    1. In Vitro ADMET Laboratories, Columbia, MD
    Search for more papers by this author
  • Albert P. Li,

    1. In Vitro ADMET Laboratories, Columbia, MD
    Search for more papers by this author
  • Rosanne Spolski,

    1. Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Erin E. West,

    1. Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Yrina Rochman,

    1. Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
    Search for more papers by this author
  • Warren J. Leonard,

    1. Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Mohammed Bourdi,

    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    Search for more papers by this author
  • Lance R. Pohl

    Corresponding author
    1. Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD
    • Address reprint requests to: Lance R. Pohl, Pharm.D., Ph.D., Molecular and Cellular Toxicology Section, Laboratory of Molecular Immunology, National Heart, Lung and Blood Institute, National Institutes of Health, Building 10, Room 8N110, 10 Center Drive, Bethesda, MD 20892-1760. E-mail: pohll@nih.gov; fax: 301-480-4852.

    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

  • See Editorial on Page 1473

  • This work was supported by the Intramural Research Program of the National Institutes of Health and the National Heart, Lung and Blood Institute.

Abstract

Liver eosinophilia has been associated with incidences of drug-induced liver injury (DILI) for more than 50 years, although its role in this disease has remained largely unknown. In this regard, it was recently shown that eosinophils played a pathogenic role in a mouse model of halothane-induced liver injury (HILI). However, the signaling events that drove hepatic expression of eosinophil-associated chemokines, eotaxins, eosinophil infiltration, and subsequent HILI were unclear. We now provide evidence implicating hepatic epithelial-derived cytokine thymic stromal lymphopoietin (TSLP) and type 2 immunity, in particular, interleukin-4 (IL-4) production, in mediating hepatic eosinophilia and injury during HILI. TSLP was constitutively expressed by mouse hepatocytes and increased during HILI. Moreover, the severity of HILI was reduced in mice deficient in either the TSLP receptor (TSLPR) or IL-4 and was accompanied by decreases in serum levels of eotaxins and hepatic eosinophilia. Similarly, concanavalin A–induced liver injury, where type 2 cytokines and eosinophils play a significant role in its pathogenesis, was also reduced in TSLPR-deficient mice. Studies in vitro revealed that mouse and human hepatocytes produce TSLP and eotaxins in response to treatment with combinations of IL-4 and proinflammatory cytokines IL-1β and tumor necrosis factor alpha. Conclusion: This report provides the first evidence implicating roles for hepatic TSLP signaling, type 2 immunity, and eosinophilia in mediating liver injury caused by a drug. (Hepatology 2014;60:1741-1752)

Ancillary